GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (XTER:SRT) » Definitions » EV-to-EBITDA

Sartorius AG (XTER:SRT) EV-to-EBITDA : 24.97 (As of May. 05, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Sartorius AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sartorius AG's enterprise value is €21,407 Mil. Sartorius AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €857 Mil. Therefore, Sartorius AG's EV-to-EBITDA for today is 24.97.

The historical rank and industry rank for Sartorius AG's EV-to-EBITDA or its related term are showing as below:

XTER:SRT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.53   Med: 21.69   Max: 61.11
Current: 24.97

During the past 13 years, the highest EV-to-EBITDA of Sartorius AG was 61.11. The lowest was 8.53. And the median was 21.69.

XTER:SRT's EV-to-EBITDA is ranked worse than
70.25% of 484 companies
in the Medical Devices & Instruments industry
Industry Median: 16.065 vs XTER:SRT: 24.97

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Sartorius AG's stock price is €223.00. Sartorius AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €2.173. Therefore, Sartorius AG's PE Ratio for today is 102.62.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sartorius AG EV-to-EBITDA Historical Data

The historical data trend for Sartorius AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG EV-to-EBITDA Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.34 41.14 39.19 17.22 27.19

Sartorius AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.45 16.89 23.09 27.19 27.94

Competitive Comparison of Sartorius AG's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Sartorius AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius AG's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sartorius AG's EV-to-EBITDA falls into.



Sartorius AG EV-to-EBITDA Calculation

Sartorius AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=21406.908/857.4
=24.97

Sartorius AG's current Enterprise Value is €21,407 Mil.
Sartorius AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €857 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius AG  (XTER:SRT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sartorius AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=223.00/2.173
=102.62

Sartorius AG's share price for today is €223.00.
Sartorius AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.173.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sartorius AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sartorius AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius AG (XTER:SRT) Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.